Froedtert to test promising antiviral drug remdesivir on coronavirus patients

Froedtert & the Medical College of Wisconsin said Wednesday it will begin administering remdesivir – an experimental COVID-19 drug that has shown some promise at fighting the coronavirus – to some of its critically ill patients.  The health system was recently granted enrollment into California-based biopharmaceutical company Gilead Sciences’ expanded access program to treat COVID-19

Already a subscriber? Log in

To continue reading this article ...

Become a BizTimes Insider today and get immediate access to our subscriber-only content and much more.

Learn More and Become an Insider

Sign up for the BizTimes email newsletter

Stay up-to-date on the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin

What's New

BizPeople

Sponsored Content

BIZEXPO | EARLY BIRD PRICING | REGISTER BY APRIL 15TH & SAVE

Stay up-to-date with our free email newsletter

Keep up with the issues, companies and people that matter most to business in the Milwaukee metro area.

By subscribing you agree to our privacy policy.

No, thank you.
BizTimes Milwaukee